The K2 Principal Fund L.P. acquires common shares of Tribute Pharmaceuticals Canada Inc.
Jul 13, 2015, 09:38 ET
TORONTO, July 13, 2015 /CNW/ - The K2 Principal Fund L.P. ("K2") announced that it has acquired 10,659,925 common shares and 4,700,000 common share purchase warrants (the "Warrants") to purchase up to 4,700,000 common shares of Tribute Pharmaceuticals Canada Inc. (TRX) at an exercise price of $0.90 per share. The warrants expire on July 15th, 2016. As a result of the acquisition of such shares and previously purchased warrants, and assuming the exercise of the Warrants in full, the Partnership would own 15,359,925 common shares, representing approximately 12.97% of the issued and outstanding common shares of TRX.
K2 acquired the securities for investment purposes only and may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over, or exercise its current rights to acquire, common shares or other securities of TRX through market transactions, private agreements or otherwise.
SOURCE K2 Principal Fund L.P.
For further information: Dan Gosselin, The K2 Principal Fund L.P., (416) 365-2155
Share this article